ARTICLE | Emerging Company Profile
NextRNA: small molecules take on lncRNA-protein interactions
With $56M, the Dana-Farber spinout is developing RNA- and protein-targeting therapies for cancer and immunology
March 3, 2022 12:43 AM UTC
Armed with platforms for lncRNA-based target discovery and small molecule design, NextRNA aims to drug interactions between the non-coding RNAs and the proteins through which they drive disease pathology.
“I really think this novel class of targets is so untapped,” co-founder, CSO and interim CEO Dominique Verhelle told BioCentury. Before starting NextRNA Therapeutics Inc., Verhelle was head of strategic academic alliances in the External Innovation Center at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). ...